Case Report: RAB10-ALK: A Novel ALK Fusion in a Patient With Gastric Cancer
Autor: | Shurong Zhang, Jiankun Liu, Hushan Zhang, Dun Xiong, Bitao Li, Raomei Li, Zheng-Qi Wen |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Alectinib Cancer Research Brigatinib medicine.drug_class Case Report lcsh:RC254-282 Tyrosine-kinase inhibitor 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases medicine cancer anaplastic lymphocyte kinase-tyrosine kinase inhibitor next generation sequencing Crizotinib Ceritinib Kinase business.industry gastric cancer Cancer anaplastic lymphocyte kinase fusion medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Lorlatinib respiratory tract diseases 030104 developmental biology Oncology 030220 oncology & carcinogenesis Cancer research business medicine.drug |
Zdroj: | Frontiers in Oncology Frontiers in Oncology, Vol 11 (2021) |
ISSN: | 2234-943X |
Popis: | Gastric cancer is one of the most common cancers, while the current treatment options for gastric cancer are relatively scarce due to insufficient understanding of molecular characteristics and subtypes of gastric cancer. Different gene rearrangements of anaplastic lymphocyte kinase (ALK) have been reported in several types of cancer, especially in NSCLC. The first-generation ALK tyrosine kinase inhibitor (TKI) crizotinib, second-generation (ceritinib, alectinib, and brigatinib) and third-generation (lorlatinib) ALK-TKIs have been widely used for NSCLC patients with ALK rearrangement. However, little was reported about ALK mutation in gastric cancer (GC). Here we identified a novel form of ALK fusion, a case of GC with RAB10-ALK fusion, and this is the first report of ALK fusion in gastric cancer. |
Databáze: | OpenAIRE |
Externí odkaz: |